FDA approved L-glutamine powder for the treatment of sickle cell disease - Katalyst HLS

On July 7, 2017, the U.S. Food and Drug Administration approved L-glutamine oral powder (Endari, Emmaus Medical, Inc.) for oral administration to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years and older. @Katalyst HealthCares & Life Sciences Inc.,
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm566097.htm